Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EBIT (2016 - 2025)

Historic EBIT for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $51.3 million.

  • CorMedix's EBIT rose 166193.24% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.0 million, marking a year-over-year increase of 32716.67%. This contributed to the annual value of -$22.4 million for FY2024, which is 5433.54% up from last year.
  • CorMedix's EBIT amounted to $51.3 million in Q3 2025, which was up 166193.24% from $19.5 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's EBIT ranged from a high of $51.3 million in Q3 2025 and a low of -$16.7 million during Q1 2024
  • Over the past 5 years, CorMedix's median EBIT value was -$7.5 million (recorded in 2021), while the average stood at -$1.4 million.
  • Per our database at Business Quant, CorMedix's EBIT plummeted by 5666.4% in 2023 and then skyrocketed by 166193.24% in 2025.
  • Quarter analysis of 5 years shows CorMedix's EBIT stood at -$7.8 million in 2021, then decreased by 7.83% to -$8.4 million in 2022, then dropped by 24.77% to -$10.5 million in 2023, then skyrocketed by 223.59% to $12.9 million in 2024, then surged by 296.92% to $51.3 million in 2025.
  • Its EBIT was $51.3 million in Q3 2025, compared to $19.5 million in Q2 2025 and $20.1 million in Q1 2025.